Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bacTRL-Spike for Prevention of COVID-19 in Healthy Adults
NCT04334980Phase 1Completed
- Sponsor
- Symvivo Corporation
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bacTRL-Spike in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Symvivo Corporation. Primary endpoint: Frequency of Adverse Events. Started Nov 2020; status: completed.
02
Drugs
bacTRL-Spike
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04334980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334980.